Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
NEU | Ann: 2023 Annual Report to shareholders | 13:25 | 62 | 18K | |||
|
|||||||
NEU | Share Price | 12:48 | 9.9K | 4.4M | |||
|
|||||||
NEU | Ann: Q1 2024 quarterly activity and cash flow report | 12:08 | 8 | 2.2K | |||
|
|||||||
NEU | Ann: Neuren completes enrolment in Pitt Hopkins Phase 2 trial | 11:47 | 92 | 39K | |||
|
|||||||
NEU | Ann: Trofinetide accepted for Priority Review by Health Canada | 23/04/24 | 8 | 4K | |||
|
|||||||
NEU | TROFINETIDE PRIORITY REVIEW IN CANADA | 23/04/24 | 3 | 2.0K | |||
|
|||||||
NEU | Ann: Appendix 4G | 23/04/24 | 0 | 399 | |||
|
|||||||
NEU | Ann: Completion of enrolment in Neuren's Angelman P2 trial | 19/04/24 | 48 | 27K | |||
|
See All Discussions
Timeline
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
View More |